Evaluating buprenorphine to treat cancer pain: a systematic review protocol.

ABSTRACT:

Background

Many patients with cancer experience pain related to their disease. Opioids are commonly used for moderate-to-severe cancer-related pain but carry significant side effects that may worsen quality of life. Buprenorphine, a partial mu opioid receptor (MOR) agonist, is increasingly used for the management of cancer-related pain. Although well studied as a treatment for opioid use disorder, its role in managing cancer pain is less understood.

Methods

We aim to systematically gather, assess, and summarize prior studies on the impact of buprenorphine upon cancer-related pain. Cochrane CENTRAL, OVID Medline, EMBASE, EBSCO, and Web of Science will be searched in September 2025 for any studies available to date. Studies involving buprenorphine as an intervention upon cance

SUBMITTER: Khateeb R 

PROVIDER: S-EPMC12599013 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature